Article information
Full text is only aviable in PDF
References
[1.]
N. Goodson, J. Marks, M. Lunt, D. Symmons.
Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s.
Ann Rheum Dis, 64 (2005), pp. 1595-1601
[2.]
D.H. Solomon, E.W. Karlson, E.B. Rimm, C.C. Cannuscio, L.A. Mandl, J.E. Manson, et al.
Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis.
Circulation, 107 (2003), pp. 1303-1307
[3.]
M. González-Gay, C. González-Juanatey, J. Martin.
Rheumatoid arthritis: A disease associated with accelerated atherogenesis.
Semin Arthritis Rheum, 35 (2005), pp. 8-17
[4.]
I. del Rincón, K. Williams, M.P. Stern, G.L. Freeman, A. Escalante.
High incidence of cardiovascular events in rheumatoid arthritis cohort not explained by traditional cardiac risk factors.
Arthritis Rheum, 44 (2001), pp. 2737-2745
[5.]
M.A. González-Gay, C. González-Juanatey, M.J. López-Díaz, A. Piñeiro, C. García-Porrua, J.A. Miranda-Filloy, et al.
HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis.
Arthritis Rheum, 57 (2007), pp. 125-132
[6.]
P.J. Nicola, H. Maradit-Kremers, V.L. Roger, S.J. Jacobsen, C.S. Crowson, K.V. Ballman, et al.
The risk of congestive heart failure in rheumatoid arthritis: A population- based study over 46 years.
Arthritis Rheum, 52 (2005), pp. 412-420
[7.]
M.A. González-Gay, C. González-Juanatey, T.R. Vázquez-Rodríguez, J. Martin, J. Llorca.
Endothelial dysfunction, carotid intima-media thickness, and accelerated atherosclerosis in rheumatoid arthritis.
Semin Arthritis Rheum, 38 (2008), pp. 67-70
[8.]
C. González-Juanatey, A. Testa, A. García-Castelo, C. García-Porruá, J. Llorca, W.E. Ollier, et al.
Echocardiographic and Doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease.
Semin Arthritis Rheum, 33 (2004), pp. 231-238
[9.]
M.A. González-Gay, C. González-Juanatey, J. Martin.
Inflammation and endothelial dysfunction in rheumatoid arthritis.
Clin Exp Rheumatol, 24 (2006), pp. 115-117
[10.]
C. González-Juanatey, A. Testa, A. García-Castelo, C. García-Porrúa, J. Llorca, J. Vidan, et al.
HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis.
Am J Med, 114 (2003), pp. 647-652
[11.]
G. Vaudo, S. Marchesi, R. Gerli, R. Allegrucci, A. Giordano, D. Siepi, et al.
Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity.
Ann Rheum Dis, 63 (2004), pp. 31-35
[12.]
C. González-Juanatey, J. Llorca, A. Testa, J. Revuelta, C. García-Porrua, M.A. González-Gay.
Increased prevalence of severe subclinical atherosclerotic findings in longterm treated rheumatoid arthritis patients without clinically evident atherosclerotic disease.
Medicine (Baltimore), 82 (2003), pp. 407-413
[13.]
M.A. González-Gay, C. González-Juanatey, A. Piñeiro, C. García-Porrua, A. Testa, J. Llorca.
High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis.
J Rheumatol, 32 (2005), pp. 1219-1223
[14.]
González-Juanatey C, Llorca J, Martin J, González-Gay M.A. Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum. March 11, 2008. [In press].
[15.]
E. Krishnan, V.B. Lingala, G. Singh.
Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis.
Circulation, 110 (2004), pp. 1774-1779
[16.]
D. Krause, B. Schleusser, G. Herborn, R. Rau.
Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis.
Arthritis Rheum, 43 (2000), pp. 14-21
[17.]
H.K. Choi, M.A. Hernan, J.D. Seeger, J.M. Robins, F. Wolfe.
Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study.
Lancet, 359 (2002), pp. 1173-1177
[18.]
L. Carmona, M.A. Descalzo, E. Pérez-Pampin, D. Ruiz-Montesinos, A. Erra, T. Cobo, BIOBADASER and EMECAR Groups, et al.
All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists.
Ann Rheum Dis, 66 (2007), pp. 880-885
[19.]
D. Hürlimann, A. Forster, G. Noll, F. Enseleit, R. Chenevard, O. Distler, et al.
Anti- tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis.
Circulation, 106 (2002), pp. 2184-2187
[20.]
C. González-Juanatey, A. Testa, A. García-Castelo, C. García-Porrua, J. Llorca, M.A. González-Gay.
Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody.
Arthritis Rheum, 51 (2004), pp. 447-450
[21.]
C. González-Juanatey, J. Llorca, A. Sánchez-Andrade, C. García-Porrua, J. Martin, M.A. González-Gay.
Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab.
Clin Exp Rheumatol, 24 (2006), pp. 309-312
[22.]
C. González-Juanatey, J. Llorca, T.R. Vázquez-Rodríguez, N. Díaz-Varela, H. García-Quiroga, M.A. Gonzá lez-Gay.
Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy.
Arthritis Rheum, 59 (2008), pp. 1821-1824
[23.]
C. González-Juanatey, J. Llorca, C. García-Porrua, J. Martin, M.A. González-Gay.
Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis.
Arthritis Rheum, 55 (2006), pp. 150-153
[24.]
F. del Porto, B. Laganà, S. Lai, I. Nofroni, F. Tinti, M. Vitale, et al.
Response to antitumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis.
Rheumatology (Oxford), 46 (2007), pp. 1111-1115
[25.]
D.W. McCarey, I.B. McInnes, R. Madhok, R. Hampson, O. Scherbakov, I. Ford, et al.
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): Double-blind, randomi- sed placebo-controlled trial.
Lancet, 363 (2004), pp. 2015-2021
[26.]
F. Hermann, A. Forster, R. Chenevard, F. Enseleit, D. Hürlimann, R. Corti, et al.
Simvastatin improves endothelial function in patients with rheumatoid arthritis.
J Am Coll Cardiol, 45 (2005), pp. 461-464
[27.]
V. Gil-Guillén, D. Orozco-Beltrán, A. Maiques-Galán, J. Aznar-Vicente, J. Navarro, L. Cea-Calvo, et al.
Agreement between REGICOR and SCORE scales in identifying high cardiovascular risk in the Spanish population.
Rev Esp Cardiol, 60 (2007), pp. 1042-1050
[28.]
van Halm V.P, Peters M.J, Voskuyl A.E, Boers M, Lems W.F, Dijkmans B, et al. Rheumatoid arthritis versus type 2 diabetes as a risk factor for cardiovascular disease, a cross-sectional study. The CARRE Investigation. Ann Rheum Dis. Aug 12, 2008. [In press].
[29.]
S. Sihvonen, M. Korpela, A. Mustila, J. Mustonen.
The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheuma- toid arthritis.
J Rheumatol, 32 (2005), pp. 2089-2094
[30.]
Snir O, Widhe M, von Spee C, Lindberg J, Padyukov L, Lundberg K, et al. Multiple antibody reactivities to citrullinated antigens in sera from rheuma- toid arthritis patients-association with HLA-DRB1 alleles. Ann Rheum Dis. Jul 17, 2008. [In press].
[31.]
Peters M.J, Symmons D, McCarey D, Dijkmans B.A, González-Gay M.A, Kitas G, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis: Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2009. [In press].
Copyright © 2009. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
